New herpes drug enters early human testing
NCT ID NCT06385327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called ABI-5366 in 115 people to see if it is safe and how the body processes it. Part A involved healthy volunteers receiving a single dose, while Part B included people with recurrent genital herpes who received multiple doses. The goal is to gather safety and dosing information for future studies, not to cure the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GENITAL HERPES SIMPLEX TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Canopy Beaches Clinical Research
Sydney, New South Wales, 2100, Australia
-
Canopy Clinical Sutherland
Miranda, New South Wales, 2228, Australia
-
Canopy Clinical Wollongong
Wollongong, New South Wales, 2500, Australia
-
East Sydney Doctors
Darlinghurst, New South Wales, 2010, Australia
-
Momentum Clinical Research
Sydney, New South Wales, 2010, Australia
-
Momentum Kapiti
Waikanae, 5036, New Zealand
-
Momentum Palmerston North
Palmerston North, 4414, New Zealand
-
Momentum Sunshine
Melbourne, Victoria, 3021, Australia
-
New Zealand Clinical Research
Auckland, 1010, New Zealand
-
New Zealand Clinical Research Christchurch
Christchurch, 8011, New Zealand
-
Pacific Clinical Research Network - Hamilton
Hamilton, 3200, New Zealand
-
Pacific Clinical Research Network - Rotorua
Rotorua, 3010, New Zealand
-
Pacific Clinical Research Network - Tasman
Nelson, 7011, New Zealand
-
Pacific Clinical Research Network - Wellington
Upper Hutt, 5018, New Zealand
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.